Markella V Zanni
Overview
Explore the profile of Markella V Zanni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
2029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ebong I, Appiah D, Mauricio R, Narang N, Honigberg M, Ilonze O, et al.
JACC Adv
. 2025 Mar;
4(4):101650.
PMID: 40088731
Heart failure (HF) is a significant cause of morbidity and mortality. Although there are inconsistencies, epidemiological studies have implicated sex hormones (SHs) in pathways that are linked to HF. The...
2.
Grinspoon S, Zanni M, Triant V, Kantor A, Umbleja T, Diggs M, et al.
Lancet HIV
. 2025 Jan;
12(2):e118-e129.
PMID: 39832519
Background: Risk estimation is an essential component of cardiovascular disease prevention among people with HIV. We aimed to characterise how well atherosclerotic cardiovascular disease (ASCVD) risk scores used in clinical...
3.
Kolossvary M, Schnittman S, Zanni M, Fitch K, Fichtenbaum C, Aberg J, et al.
JAMA Cardiol
. 2024 Dec;
10(3):254-264.
PMID: 39661372
Importance: In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene...
4.
Durbin C, Hutchison A, Colecchi T, Mulligan J, Bodepudi S, Zanni M, et al.
Rev Endocr Metab Disord
. 2024 Nov;
26(1):113-124.
PMID: 39556160
Individuals in the United States with lower economic resources face a disproportionate burden of obesity and co-morbid conditions. This review summarizes the efficacy of MR programs for the treatment of...
5.
Zanni M, Umbleja T, Fichtenbaum C, Fitch K, McCallum S, Aberg J, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae574.
PMID: 39435321
Background: Among people with HIV (PWH), COVID-19 is common and potentially severe. We leveraged REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) to assess the effects of statin therapy...
6.
Fitch K, Zanni M, Manne-Goehler J, Diggs M, Gattu A, Currier J, et al.
Ann Intern Med
. 2024 Oct;
177(11):1449-1461.
PMID: 39374532
Background: REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) led to new guidelines for statin use among people with HIV (PWH) with low to moderate risk for atherosclerotic cardiovascular...
7.
deFilippi C, McCallum S, Zanni M, Fitch K, Diggs M, Bloomfield G, et al.
JACC Adv
. 2024 Sep;
3(9):101206.
PMID: 39253712
Background: Coronary plaque is common among people with HIV (PWH) with low-to-moderate traditional atherosclerotic cardiovascular disease (ASCVD) risk. Objectives: The purpose of this study was to determine the association of...
8.
Grinspoon S, Lu M, Zanni M, Diggs M, Chu S, Ribaudo H, et al.
HIV Med
. 2024 Aug;
25(12):1283-1288.
PMID: 39183475
No abstract available.
9.
Erlandson K, Umbleja T, Ribaudo H, Schrack J, Overton E, Fichtenbaum C, et al.
Clin Infect Dis
. 2024 Aug;
80(2):425-433.
PMID: 39159048
Background: Little is known about the potential benefits or harms of statins on physical function among people with human immunodeficiency virus (PWH). Methods: REPRIEVE was a double-blind randomized controlled trial...
10.
Karady J, Lu M, Bergstrom G, Mayrhofer T, Taron J, Foldyna B, et al.
JACC Adv
. 2024 Jun;
3(6):100968.
PMID: 38938873
Background: People with HIV (PWH) have a high burden of coronary plaques; however, the comparison to people without known HIV (PwoH) needs clarification. Objectives: The purpose of this study was...